Zevra Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Nov. 12, 2024GlobeNewsWire • 10/31/24
Earnings Preview: Zevra Therapeutics (ZVRA) Q3 Earnings Expected to DeclineZacks Investment Research • 10/29/24
Zevra Therapeutics to Participate in Rare Disease Panel at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLCGlobeNewsWire • 10/10/24
Zevra Therapeutics (ZVRA) Moves 9.1% Higher: Will This Strength Last?Zacks Investment Research • 09/25/24
Zevra Therapeutics to Present Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at Sleep Europe 2024GlobeNewsWire • 09/24/24
Zevra Therapeutics' MIPLYFFA™ (arimoclomol) Receives U.S. FDA Approval as Treatment for Niemann-Pick Disease Type CGlobeNewsWire • 09/20/24
Zevra Therapeutics Presented New Data for Arimoclomol and OLPRUVA® (Sodium Phenylbutyrate) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual SymposiumGlobeNewsWire • 09/06/24
Zevra Therapeutics Announces Pricing of Underwritten Offering of Common StockGlobeNewsWire • 08/09/24
Zevra Therapeutics to Present at Canaccord Genuity's 44th Annual Growth ConferenceGlobeNewsWire • 08/07/24
Earnings Preview: Zevra Therapeutics (ZVRA) Q2 Earnings Expected to DeclineZacks Investment Research • 08/06/24
FDA Advisory Committee Votes Favorably that the Data Support Arimoclomol as Effective Treatment for Patients with Niemann-Pick Disease Type CGlobeNewsWire • 08/02/24
Zevra Therapeutics (ZVRA) Surges 21.9%: Is This an Indication of Further Gains?Zacks Investment Research • 07/10/24
Zevra Therapeutics Transitions to Orsini as the Specialty Pharmacy Provider for OLPRUVA® (sodium phenylbutyrate), a Treatment for Certain Urea Cycle DisordersPRNewsWire • 06/18/24
Zevra Therapeutics Announces Positive Final Results from Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at SLEEP 2024 Annual MeetingGlobeNewsWire • 06/03/24
Zevra Therapeutics (ZVRA) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/08/24
Zevra Therapeutics Reports First Quarter 2024 Financial Results and Corporate UpdatesGlobeNewsWire • 05/08/24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRAPRNewsWire • 05/06/24